Wells Fargo Maintains Overweight on Insmed, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Tiago Fauth maintains an Overweight rating on Insmed (NASDAQ:INSM) and keeps the price target at $55.
April 01, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo analyst Tiago Fauth reaffirms an Overweight rating on Insmed with a $55 price target.
The reaffirmation of an Overweight rating and a $55 price target by a Wells Fargo analyst could positively influence investor sentiment towards Insmed, potentially driving up its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100